Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
Novartis Pharmaceuticals
Scientific Title
Phase I Open Label, Multi-center Study to Characterize the Safety, Tolerability and Pharmacokinetics of Intravenously Administered MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma